These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12728856)

  • 21. Maraviroc--new HIV drug. Emerging options need to be used wisely.
    Vázquez E
    Posit Aware; 2007; 18(4):18-9. PubMed ID: 17682275
    [No Abstract]   [Full Text] [Related]  

  • 22. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
    Sharp M; Camp R
    GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 24. Fuzeon combination highly effective.
    AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

  • 26. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

  • 27. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 28. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging drugs in the fight against HIV disease.
    Rosenthal E
    HRSA Careaction; 2003 Feb; ():1-8. PubMed ID: 12739497
    [No Abstract]   [Full Text] [Related]  

  • 30. T-20 phase III studies underway.
    Giles C
    Surviv News (Atlanta Ga); 2001 Oct; ():1, 12. PubMed ID: 11708190
    [No Abstract]   [Full Text] [Related]  

  • 31. T-20: entirely new antiretroviral.
    James JS
    AIDS Treat News; 1997 Sep; (No 279):5-6. PubMed ID: 11364691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Darunavir (Prezista) for HIV infection.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):74-5. PubMed ID: 16977286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 34. A look ahead at this year's drug approvals.
    Proj Inf Perspect; 2007 Apr; (43):4-7. PubMed ID: 17684824
    [No Abstract]   [Full Text] [Related]  

  • 35. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 36. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental drug quickly suppresses HIV.
    AIDS Read; 2005 Apr; 15(4):150. PubMed ID: 15844233
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA gives salvage therapy testing a push forward.
    Bass E
    AIDS Treat News; 2001 Mar; (362):3-7, 1. PubMed ID: 11569956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 40. T-1249 development hits a snag.
    AIDS Clin Care; 2004 Feb; 16(2):15. PubMed ID: 15032178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.